Hematology/Oncology

Top Story

Second malignancies, death common among cancer survivors

Second malignancies, death common among cancer survivors
July 25, 2016

Approximately one in 12 patients with a common primary tumor were diagnosed with a second primary malignancy between 1992 and 2008, according to results of a SEER analysis.

Further, more than one-half of these patients died of their second malignancy. Lung cancer was the most common second primary malignancy.

Lymphocytic thyroiditis yields high prevalence of benign cervical lymph nodes

July 25, 2016
Fewer central neck compartment metastatic lymph nodes and more reactive benign cervical lymph nodes were found in patients with lymphocytic thyroiditis compared with…

Fox Chase Cancer Center announces staff appointments

July 25, 2016
Fox Chase Cancer Center announced three staff appointments. Rajeswari Nagarathinam , MD, has joined the department of pathology at Fox…
In the Journals

Temporal mutation profile discerns which patients with HBV will develop HCC

July 25, 2016
Researchers from Taiwan developed a temporal mutation profile that discerned which patients with hepatitis B virus are more likely to develop hepatocellular carcinoma…
In the Journals

Omega 3 intake linked to lower risk for death from colorectal cancer

July 25, 2016
Higher intake of omega 3 fatty acids from oily fish after a diagnosis of colorectal cancer was associated with a reduced risk for cancer-specific mortality, according to…
More News Headlines »
CME

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Video

VIDEO: CDK 4/6 inhibitors demonstrate “meaningful benefits” in metastatic, ER–positive breast cancer

July 6, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis…
More »
Current Issues
View the Current Issue
HemOnc Today